Drug has “no additional benefit” in metastatic liposarcoma, says IQWiG.
German pricing rules hit Eisai’s Halaven
The top 10 pharma milestones of the year to date.
The biggest pharma stories of 2016 so far
Cost effectiveness agency critical of real world evidence plans
German watchdog criticises EMA adaptive pathways approval